News & Events

Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology

Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology

Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022

Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022

Lung Cancer Research Foundation Welcomes New Members of Board of Directors breaking news SonDakika-Haberleri.Net

Lung Cancer Research Foundation Welcomes New Members of Board of Directors breaking news SonDakika-Haberleri.Net

Experiences along the diagnostic pathway for patients with advanced lung cancer in the USA: a qualitative study

Experiences along the diagnostic pathway for patients with advanced lung cancer in the USA: a qualitative study

LUNGevity Launches Campaign Focused on Increasing Lung Cancer Survival by Driving Awareness of Comprehensive Biomarker Testin...

LUNGevity Launches Campaign Focused on Increasing Lung Cancer Survival by Driving Awareness of Comprehensive Biomarker Testin...

LUNGevity Welcomes Amy C. Moore, PhD, as Vice President of Global Engagement and Patient Partnerships

LUNGevity Welcomes Amy C. Moore, PhD, as Vice President of Global Engagement and Patient Partnerships

Guardant Health Joins Forces With Patient Advocacy Groups to Raise Awareness of Importance of Complete Biomarker Testing for Patients With Advanced Colorectal Cancer

Guardant Health Joins Forces With Patient Advocacy Groups to Raise Awareness of Importance of Complete Biomarker Testing for Patients With Advanced Colorectal Cancer

LUNGevity Foundation Amplifies Efforts to Improve Lung Cancer Patient Access to Comprehensive Biomarker Testing through New Awareness Campaign

LUNGevity Foundation Amplifies Efforts to Improve Lung Cancer Patient Access to Comprehensive Biomarker Testing through New Awareness Campaign

FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations

FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations

A qualitative study of online support communities for lung cancer survivors on targeted therapies

A qualitative study of online support communities for lung cancer survivors on targeted therapies